Recon: FDA approves Bristol Myers’ schizophrenia drug; Roche targets $3B in annual obesity drug sales
ReconJason Scott
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)